Trial · NCT05270525
Registered outcomes33
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Absolute Change From Baseline in Sputum Neutrophil Cell Numbers | Baseline and 8 Weeks | The Absolute change from baseline in sputum neutrophil cell numbers will be reported. |
| Secondary | Absolute Change in Cell Numbers From Baseline in Sputum Cell Counts | Baseline and 8 Weeks | Absolute change in cell numbers from baseline in sputum cell counts (eosinophils, basophils, macrophages, lymphocytes, total cells) will be reported. |
| Secondary | Percent Change From Baseline in Sputum Cell Counts | Baseline and 8 Weeks | Percent change from baseline in sputum cell counts (neutrophils, eosinophils, basophils, macrophages, lymphocytes, and total cells) will be reported. |
| Secondary | Percent Change From Baseline in Cytokines | Baseline and 8 Weeks | Percent Change From Baseline in Cytokines will be reported. |
| Secondary | Percent Change From Baseline in Proteases | Baseline and 8 Weeks | Percent Change From Baseline in Proteases will be reported. |
| Secondary | Percent Change From Baseline in Markers of Inflammation | Baseline and 8 Weeks | Percent Change From Baseline in Markers of Inflammation will be reported. |
| Secondary | Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in FEV1 at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in FEV1 at 8 Weeks | Baseline and 8 Weeks | Change from baseline in FEV1 at 8 weeks during the treatment period (postdose) will be reported. |
| Secondary | Change From Baseline in Forced Vital Capacity (FVC) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in FVC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in FVC at 8 Weeks | Baseline and 8 Weeks | Change from baseline in FVC at 8 weeks during the treatment period (postdose) will be reported. |
| Secondary | Change From Baseline in Residual Volume (RV) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in RV at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in RV at 8 Weeks | Baseline and 8 Weeks | Change from baseline in RV at 8 weeks (postdose) during the treatment period will be reported. |
| Secondary | Change From Baseline in Functional Residual Capacity (FRC) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in FRC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in FRC at 8 Weeks | Baseline and 8 Weeks | Change from baseline in FRC at 8 weeks (postdose) during the treatment period will be reported. |
| Secondary | Change From Baseline in Total Lung Capacity (TLC) at 4 Weeks | Baseline and 4 Weeks | Change from baseline in TLC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported. |
| Secondary | Change From Baseline in TLC at 8 Weeks | Baseline and 8 Weeks | Change from baseline in TLC at 8 weeks (postdose) during the treatment period will be reported. |
| Secondary | Number of Participants Who Experience One or More Adverse Events (AEs) | Up to approximately 8 Weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Number of participants who experience one or more adverse events will be reported. |
| Secondary | Change From Baseline in Systolic Blood Pressure | Baseline and 8 Weeks | Change from baseline in systolic blood pressure will be reported. |
| Secondary | Change From Baseline in Diastolic Blood Pressure | Baseline and 8 Weeks | Change from baseline in diastolic blood pressure will be reported. |
| Secondary | Change From Baseline in Heart Rate | Baseline and 8 Weeks | Change from baseline in heart rate will be reported. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05270525/registered